0001193125-12-054581.txt : 20120213 0001193125-12-054581.hdr.sgml : 20120213 20120213080325 ACCESSION NUMBER: 0001193125-12-054581 CONFORMED SUBMISSION TYPE: SC TO-T/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20120213 DATE AS OF CHANGE: 20120213 GROUP MEMBERS: INTA ACQUISITION CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INHIBITEX, INC. CENTRAL INDEX KEY: 0001274913 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 742708737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79900 FILM NUMBER: 12595255 BUSINESS ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 678-746-1100 MAIL ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: INHIBITEX INC DATE OF NAME CHANGE: 20031231 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INHIBITEX, INC. CENTRAL INDEX KEY: 0001274913 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 742708737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79900 FILM NUMBER: 12595256 BUSINESS ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 678-746-1100 MAIL ADDRESS: STREET 1: 9005 WESTSIDE PARKWAY CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: INHIBITEX INC DATE OF NAME CHANGE: 20031231 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC TO-T/A BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 SC TO-T/A 1 d300083dsctota.htm AMENDMENT NO. 6 TO SCHEDULE TO Amendment No. 6 to Schedule TO

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

Amendment No. 5

 

 

 

INHIBITEX, INC.

(Name of Subject Company (Issuer))

 

INTA ACQUISITION CORPORATION

(Offeror)

A Wholly Owned Subsidiary of

 

BRISTOL-MYERS SQUIBB COMPANY

(Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

 

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

45719T103

(CUSIP Number of Class of Securities)

 

Sandra Leung, Esq.

General Counsel & Corporate Secretary

P. Joseph Campisi, Jr., Esq.

Vice President & Associate General Counsel

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

 

 

Copies to:

 

David Fox, Esq.

Daniel Wolf, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

(212) 446-4800

CALCULATION OF FILING FEE

 

 

Transaction Valuation(1)   Amount of Filing Fee(2)
$2,529,313,507.44   $289,859.33

 

 

(1) Calculated solely for purposes of determining the filing fee. The calculation assumes the purchase of 80,398,198 shares of voting common stock, par value $0.001 per share. The transaction value also includes the aggregate offer price for 17,943,006 shares issuable pursuant to outstanding options and warrants with an exercise price less than $26.00 per share, which is calculated by multiplying the number of shares underlying such outstanding options at each exercise price therefor by an amount equal to $26.00 minus such exercise price.
(2) The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #3 for fiscal year 2012, issued September 29, 2011, by multiplying the transaction value by 0.0001146.

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

Amount Previously Paid: $289,859.33    Filing Party: Bristol-Myers Squibb Company and Inta Acquisition Corporation
Form of Registration No.: Schedule TO    Date Filed: January 13, 2012

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  x Third-party tender offer subject to Rule 14d-1.
  ¨ Issuer tender offer subject to Rule 13e-4.
  ¨ Going-private transaction subject to Rule 13e-3.
  x Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.  ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

  ¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  ¨ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

 


This Amendment No. 5 to the Tender Offer Statement on Schedule TO (the “Schedule TO”) amends and supplements the Schedule TO relating to the tender offer by (i) Inta Acquisition Corporation, a Delaware corporation (“Purchaser”) and a wholly-owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and (ii) Parent, for all of the outstanding common stock, par value $0.001 per share (the “Shares”), of Inhibitex, Inc., a Delaware corporation (the “Company”), at a price of $26.00 per share net to the seller in cash without interest and less applicable withholding taxes, if any, upon the terms and conditions set forth in the offer to purchase dated January 13, 2012 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, together with any amendments or supplements, collectively constitute the “Offer.”

All information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and 11 in the Schedule TO, and is supplemented by the information specifically provided in this Amendment No. 5.

This Amendment No. 5 is being filed to amend and supplement Items 1, 4 8 and 11 as reflected below.

Items 1, 4, 8 and 11

Items 1, 4, 8 and 11 of the Schedule TO are hereby amended and supplemented by adding the following text thereto:

“The Offer and withdrawal rights expired at midnight, New York City time, on February 10, 2012. The Depositary has advised us that 77,532,611 Shares were validly tendered and not properly withdrawn (not including 4,260,705 Shares tendered pursuant to notices of guaranteed delivery). All Shares that were validly tendered and not properly withdrawn have been accepted for payment in accordance with the terms of the Offer.

As a result of the purchase of Shares in the Offer, Purchaser and Parent will have sufficient voting power to approve the Merger without the affirmative vote of any other stockholder of the Company. Accordingly, Purchaser and Parent intend to effect a “short form” merger in which Purchaser is merged with and into the Company, with the Company surviving the Merger and continuing as a wholly-owned subsidiary of the Parent. In the Merger, each Share issued and outstanding immediately prior to the effective time of the Merger, other than Shares held by the Company in treasury, Parent or Purchaser immediately prior to the effective time of the Merger, or any stockholder of the Company who is entitled to and properly exercises appraisal rights under Delaware law, will automatically be converted into the right to receive the Offer Price in cash, without interest and less any applicable withholding taxes. All Shares converted into the right to receive the Offer Price shall be canceled and cease to exist. In addition, upon completion of the Merger, the common stock of the company will cease to be traded on Nasdaq.

On February 13, 2012, Parent issued a press release announcing the expiration and results of the Offer. The full text of the press release is attached hereto as Exhibit (a)(13) and is incorporated herein by reference.”

Item 12

Item 12 of the Schedule TO is amended and supplemented by adding the following exhibit:

 

Exhibit
No.
   
(a)(13)   Press Release issued by Bristol-Myers Squibb Company, dated February 13, 2012.

 

2


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

INTA ACQUISITION CORPORATION
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   President
Date:   February 13, 2012
BRISTOL-MYERS SQUIBB COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   Vice President, Strategy, Alliances & Transactions
Date:   February 13, 2012


EXHIBIT INDEX

 

Exhibit

No.

   
(a)(1)(A)   Offer to Purchase, dated January 13, 2012.*
(a)(1)(B)   Letter of Transmittal (including Internal Revenue Service Form W-9).*
(a)(1)(C)   Notice of Guaranteed Delivery.*
(a)(1)(D)   Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(E)   Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(F)   Joint Press Release of Inhibitex, Inc. and Bristol-Myers Squibb Company, dated January 7, 2012 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission dated January 9, 2012).*
(a)(1)(G)   Summary Advertisement as published in the Wall Street Journal on January 13, 2012.*
(a)(5)   Press Release issued by Bristol-Myers Squibb Company, dated January 13, 2012.*
(a)(6)   Class Action Complaint dated January 11, 2012 (Charles C. Osborne and Hortensia D. Osborne v. Inhibitex, Inc., et al.).*
(a)(7)   Class Action Complaint dated January 12, 2012 (Jeremy Alber v. Inhibitex, Inc. et al.) (incorporated by reference to Exhibit (e)(14) to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 17, 2011).*
(a)(8)   Class Action Complaint dated January 13, 2012 (John P. Hegarty v. Inhibitex, Inc., et al.).*
(a)(9)   Amended Class Action Complaint dated January 19, 2012 (Jeremy Alber v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(16) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(10)   Amended Class Action Complaint dated January 20, 2012 (Charles C. Osborne, Jr. and Hortensia D. Osborne v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(17) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(11)   Class Action Complaint dated January 25, 2012 (Ferdinand Alvarez v. Inhibitex, Inc., et al.) (incorporated by reference to Exhibit (e)(18) to Amendment No. 2 to the Schedule 14D-9 filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 26, 2011).*
(a)(12)   Press Release issued by Bristol-Myers Squibb Company, dated February 3, 2012.*
(a)(13)   Press Release issued by Bristol-Myers Squibb Company, dated February 13, 2012.
(d)(1)   Agreement and Plan of Merger, dated as of January 7, 2012, by and among Inhibitex, Inc., Bristol-Myers Squibb Company, and Inta Acquisition Corporation (incorporated by reference to Exhibit 2.1 to the Form 8-K filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 10, 2012).*
(d)(2)   Tender and Support Agreement, by and among Inhibitex, Inc., Bristol-Myers Squibb Company, Inta Acquisition Corporation and certain stockholders, dated January 7, 2012 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Inhibitex, Inc. with the Securities and Exchange Commission on January 10, 2012).*

 

* Previously filed.

 

4

EX-99.(A)(13) 2 d300083dex99a13.htm PRESS RELEASE Press Release

Exhibit (a)(13)

 

LOGO

Bristol-Myers Squibb Announces Successful

Completion of Cash Tender Offer for Shares of Inhibitex, Inc.

(NEW YORK, February 13, 2012) – Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company (“Bristol-Myers”) for all of the outstanding shares of common stock of Inhibitex, Inc. (NASDAQ: INHX) (“Inhibitex”) at a purchase price of $26.00 per share. The tender offer expired at midnight, New York City time, on February 10, 2012. As of the expiration of the offer, 77,532,611 shares of common stock of Inhibitex were validly tendered and not withdrawn in the tender offer. All of such shares have been accepted for payment in accordance with the terms of the tender offer.

As a result of the tender offer, Bristol-Myers now owns, together with its affiliates, approximately 91% of the outstanding shares of Inhibitex, which will allow Bristol-Myers to complete and close the merger and acquisition of Inhibitex today without stockholder approval. Upon completion of the merger, Inhibitex will become a wholly-owned subsidiary of Bristol-Myers. All outstanding shares of common stock of Inhibitex, other than shares held by Bristol-Myers or Inhibitex in treasury or shares held by Inhibitex’s stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $26.00 offer price per share without interest thereon and less any applicable withholding taxes. In addition, upon completion of the merger, the common stock of Inhibitex will cease to be traded on the NASDAQ Stock Market.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contacts

Bristol-Myers Squibb

Media: Sonia Choi, 609-252-5132, sonia.choi@bms.com; Jennifer Fron Mauer, 609-252-6579, jennifer.mauer@bms.com

Investors: Teri Loxam, 609-252-3368, teri.loxam@bms.com; Timothy Power, 609-252-7509, timothy.power@bms.com

Inhibitex

Investors: The Trout Group, Lee M. Stern, CFA, 646-378-2922, lstern@troutgroup.com

GRAPHIC 3 g300083g05u98.jpg GRAPHIC begin 644 g300083g05u98.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`)`#F`P$1``(1`0,1`?_$`+,````&`P$!```````` M```````!`@<("00&"@,%`0`!!0$!`0```````````````00%!@<""`,0```& M`0(%`04#"0(/``````$"`P0%!@<1"``A$A,)%3%!(A068:$7\%%Q@<'A(R08 MD='Q,D)B3"6A)"2] M("533FVKJ&K\Y4$),Z[=I'&D&J2KUXN"8)D$IAXF,CT&:VPC9NPNHKF*./FZ M4"LHY<3Q(=UDXFI;@2%`\:G4'C/5IN?#6H>/AH:Z?E^OA:_\M'G31=7V>_3A.5!H.V@ M`\]-.%KY:2NC$=."N]//2Z`#KP5WIHT?"Z-)$P`.@_V_LX2IK3S.C_I7Y:3U M\_9KRUUUX2OEY_X?P^>N>0\J4I72NKEKI]_Y?FX4D@ZZ_7QT.K[/\/\`9P$_ MII/CX:(#".G+3]?[N"M*?/25\O/2^%UUH<&C0X-&AP:-%KPE3Y:2N]-$!A'W M>SD/[N7!4_PT;TT8#J&O`-QI='PNC0X#HTCK#]/Z!_=[N$KY>>DJ#\-`#ZZ< MM!'W:\]/S^[A.1\0#3_CQ_32!JT!\=&`ZCI^W]W`&Y>&NO\`+2N.M&FWRK>5 M:!4'+%(2MLOU2,!7BB[L?U_E4>;%5\2-169R!QUDTT8Y73$)&M0.4C;* M*GR&[,3L%!)-`=5L6"K8IMHVFD)6HSHLG1:HRK&<)*-DH^B7#B6MWE++T[XQ`,EPQ>V4@RQVACC5 M.4/W<5X\@2OB.3CB]3E=Y8X:^,M@DNTENJI=,'$4EZ)'=@)Z<:N6XGBW@>*? M4@I\1OG"DIR4%E6Y5*".%7!2FP6UFT95@*M=+(%1RM1R8J">5.0XND9.UB1PJ(5M(F(4S+%(.92,D%PP%#059`$!8C7VMK'&V@M MX2_F4%A`TL9]+U)`I5&1C7<@+(6`\S3^/+.E2[O7L9W.Q5FT+P3*S)0\K`03V8;N3P4DH MDPD>L68DZ51$A1,!A`VG2/6`BLILY:17\?K6;W$:.G(KR5G`(Y+N-CXC?2=G MDOH.N7T^-F_'OH[65TDXA^+*C,"5;9A4>!USZX3>[C,A^*VP^0*R;\=Q58SG M&5G)N2H]1];:PAAQ$U"LDW'1%*>XW7K(03QE8RPI&NHB"HNW903#I`$C>C,[ M'UBP]W(O;^UP.-?KSS0P-_3?\BDJKSD];ER5DY%?,C%1^E0=.LR>U2Y?&/@7L_V`RM^9ZA)D9*#@(:5%?N\P:T.XKJ18R+$C MD61GK,KP"I'%J9T@5T!%C@FB86XJ=T"J*&`I1$/B,.@<5Q8IC'ZJ(WI'SI]) M^-"-OC_RU9S/"LGI,Z"2G@2.7RV\=1&VZ[M$MP.:MW6)FM+/6FVUK)-:QJ$V MXFDY%Q='TO`NIB0EBQR3)N2&9M54`213%5P=0OQ&$@_#Q<^S=/DZW@\/F))O M4;+6SS<.)7T@"H4%JGE4-4F@^6J1U7NZ=G[#FL)'"(TQ-RD(;G4RDA^34H*` M%#0`G;Q-=M2X*_9.'"[-!XT6=-``SIJDY14D&4R#<@$5'ZBM?'56VW;+.:9?R?[W,'7G*,G M<\98YQ7AFSXZJBL+!P<74/K-D$XAJDO)O$".?ES/72JBZZ29.K33C5. MQ8?!1>U>#SEA:K!E;F\N4F<,S&01!0/N)"@^/$;`UIK(>K9G/S^[.?P61NY) M\5:VENT*%558_4^HT"@`G>G([D`5U(/R'3%XJ.S?/N0\;9&M6+KOC#'UCR+7 M[-4@@U':K^J1+V10AY1"P0\TRW4%C<=SQ]AD M;:&ZL;BX6%DDY4I(P!8<2#R'B/\`'5A]U)LC8]"R64Q-U-9Y&V@,R21\>54\ M%/($%3YBGZ:CMXHMY=OW(X%L-2S^^*QW)[>I0E5S.65"/CG4M$R#(9RFY#60 M:%:L4F4]7U!*LJD0B`N&BBA="*$ULONWTFPZUV".^ZR.?5LD"]L5^KBZGC+" M/$U1_`;FC`;D'57]F._WO:NMRV?9V]/M.+?A=!Z*60@M%.?@K+4$["JEM@1J M%FUO>;N&W8^5JU4U3)=RHNUV/Q=(Y=P_CF#9UAFROE+@IV'JE9LUH=25??SQ MHC(AUGDOVDG*"HM5FP$.0G^->.V]*Z[T[VAMKU+:WG[7)>?CW$KT/:'Z=>/-@KYUK3X:]4QW"273WE4D1,!S%[JA":@D05%1#K,&H)$#4WY@#4>.5#MY5^=- MO^/A\==&1%-&('CYCR\3_P!?AK&6E(]N9`CA\Q0,Y(=5L59V@D9PFFGW%#H% M.H45B$)\0F+J`%YCQ]!%*U:*U%-#L33RW^'\=?-KB!"H=T!;PJP%1\17Q_AI M;M=5)DZ<-D/G%DFRZK=NF;07*B:)SI(E/S`!7.`%`?\`.XX0!I`KG@*@$_#> MA/\`#_GI9I'2%GB7FX5B`/,@$@?QV&N;C8Q;\Z^1RF9[M5A\@>:L'[HJ]?KK M!,<&8_5ID#3L05]BH+&KJ26.)6M.9FV1BCHRC=V],[(Y260$@JD<`!S>F>]V MF"]M;K'6\'7;&_ZG);1,;N42.]P[`-)24.%1E_E6E*$;$>'E7V_N^P^Z-EDK MJ;LV0Q_;H[F11:1-&D=NJ[1UB*%G1C4,P-05I4-N;X]OC'*%1P)BR&S]-Q,I ME>M4:"ALDV5I+'?QDS9(EJ2.?3X2SUM'J+C-"@5TH91-,W=5,`AJ'/S_`-@E MQ=[G[J7K<;KB9)V:%"*,J,:A*#E]M>(H3L!KT=UE,O8=0- M56==BX8A?NI7<"A.G:1GH9R[6CV\M%.'[>/;2R[%&19JNT8IXHX2:2BS9-8R MR4A(IK/%PEVR'%5+H6Z"I&!0G2J94-4RI&$0*H*A>9 M=!YA[./B.1:E-@*GSI_A_CKZEU"UKX[#YGY5._RU7#FJ?WL4^@;_`"W2]]Q9 M2:=3Z$ZNFU">H\$$_?X./K51E)JQ%R%$6EJI`N%Y20CBMT5`!7M"951,-"$+ MQI.%AZ-=WO7K2&VNYKR6?T[]97XQNSR*J&%HSR%`Q)&W\H-:DZRO/7'N#96' M9+R:YM(;.&#U,>T*AYD5$9G$RNI6K4`!W(/(K0`:=/Q]9'LV4MENUV[Y#M*] MHR'=<,U&SV:8E7+89NY.;U\I/8H\C,P+LQ%>1\S74; M]KV9\QRGD7\@V(,G99>6_&V(X'!;_&\-(1=?K4-3VM\BY6>=L4"1C=N#QTF+ MM-J9XY547=$0()M#DR(IWK0;%N(% M%Y'RU4>GY_.R^Z79L)F+YKC&645HT",J1K'ZHD8C:@+>`Y'=@`3JV#N%Z!4U M#HZ>OJZ@Z>G37JZM>GITYZ^S3C):/7C3ZZ^'_A^NMJY+2M?H^/E^OZ?/5;N_ MRAY`M,[@.6K;%S,U>,L=DAIF,1FP013GK'%MTJ^NZJ#MKZ'>ADDF3I@@S?.F MZ0KN"HD!91T"1M)]O\ACK.*_BNB$N6B5E8IR/%&JX#A@T?&JN64,0%+;<*ZR MCW-QF3OI\;-9H\EI',ZNJR<:,ZT0E.)63E0H%8@$MQ'W:;QW,9'DJD1A_4[3 M[&QDU%ZDABIKC4LE<7K]HV*1>FK8D6II9YD[9-^DJ[5VQ009HB518R2.BG$E M'^U17/,8QXW0:.2SE?*>N`)QUDF MW1A!H\B/4D)58PBBJLSM?0_=HK0Q`5@8<7%:T"H(:RAC2C1A^7D2=;-LHH>1(3/&9['+,7<; M4/I*KP3DJSA:N-Y*U.Y!U9F73BEO%MHFDOV$#)"[6+W$'Q4Y5,KAHBJO6-K;,K7ZS2-0*"0@`4UF+LTO)A0>(_ID!B%%7OM[B\M:]DR%Y<*R6 M)AC4\G(#2$\Q2`(JQE5)+"M1S!(!L\>S_PQE'_LB]8TQ[F. MS4BT1=WL#6J5^8I%_P`@6J%E)S'KR02[\D)(\],1&9!NN^&C^&2Y9SF;8VL M.1L_Y6PM?GM0LMAH\/?J30CE:,9-.NUI_%P$/+2\>NNQ=2$>V;.A(94J:A"= M!26.XQV/Z%?=VM>O1PM;V^.MKF$2(DI@DF8!ASD#.0#1@CDK7B2I.YKUI>WG MN-C>CWG9&G$]SD;FUE,[/ MP]8ZPPUM59I37.V78].M.;]=+!"F;FKZUE!5>-GIV19KOT).?<@FX,05R-S` MCU=LI2AG/5L_DNU=1[GE,V89;XXZ!O4]*-'KZB)L44$`JHJ/`G>E=:5V?J^( MZCW7I6,P22Q8]+ZX4)ZTCIO1O!V(J"[;TJ%JM::BW-XXBMJ>Y%XGO9QZ%IFL;B7ANL/.@$,D:JPEEA!IREWY\C]=57D0:\J5)AH MNG=H;^_+3\["9/+K-:9J!RTT3LRF.*4U:D7TE6446A8J"*<67NJ3+:]7?-9E M_!59;T_)6+-P6/L98UO,.>0&3Q14Y9@D;3*0;"TQ&1I->1<&R%'7E.76=.6ST'">I`!$$ MTP$O%%Z+V3,=S]QKGJG9Z7/6[L7:-;LJB.W6-':-H!2D)BXA04I4>-6H=7SW M"ZI@^B^VMKW+JU;7M-HUHZW2L_J7#3/&)!*>7]42(?.6%E)[7==QLMRD-D0#U[X*7$YJVR-3M3X:C!F[8[GZT9/VNY>VN2#RKUS==MMHNV?>I*1@I)^D M8S^AZ^Y5R$!3KHG3L"U08+Q#-TF!E$'J34`#^,<>+)U[OO7K/"Y/"]K59;G% M9"2\QH8[F\160&[E]G&D[T4*W,V8\K.-[9,;>&[EQF%[GUO,$?IR@24AC:)4K MJ3GN@FFM)LR"'4;3A]V13#EXO>''<4Z_<8;U%3BO`7?$6WXI0U4TF(E(`^Q6 M/B-1?756ZQ$GLED@7['!G>+N6;F;/D;EKH,"""85,2;TJZ#STW&**!);RX7= M^V5V_3699G[')UC$^QC%.)H:#C:3,I3PR1G]0EXAQ*%>-FD. MT7F;`[9"!S@0%C\2F5R$/1Y<(_YPL\#'CH;RX5$#S92:X/*5./'C(OBA:1O3 MC4B@K2D/B<5-WZ'-PC'-?=ADR,UE:R2,RV^(@@6D3U+ED8;,%1>89\MZNE<:9-?T.(XG6.K]DO+J^!PTR7#":55G,7(`4#U"G8.00T@4&0EJZ M;K=MMBB-G^3LD91R%@U7=9X^9O&U&PPYDZY6VCM24E9KG%A$6.L;$DI]?U MD^!Y@,5\&Z1J!;J&VPE3+S#VL\AC%IBZOVF-N\ZXT4>49K56DHVM$TZ40;&* MLM!I@Z=',FF(&ZA$I?8'F3(6=^9!51_P"HT&^O5N,O M\:,!!DK:;EAQ:)(LK><0C#40;TW,=W(@!DGO45-\FX2,(DV?VZ] MPLEBKQ/;;N]N;[J\\XMV@F4F2W=WX#TZ_5]+?R>0W0J?'#?-64?=2C'9U8&HB)A7.P$7M3U'.WG6C3,KFUM$N*!I8+=X1*J*Y%4<@D%Q1B&^(4BE8#/W/N_W;!8 MSMJ5PJ81[J2WJ5BN+A)3&79!3FM0K!:D+QH-BU6&S1BRG8SKOGLI6/TIRG5C M%D5MH?8_B*[:K-$HU=N]1DY)Q7V!V,LBN:GF=V=Z/HZAE(X"K:=GX2=-AP>2 MO,M==`O,D4FN;I+WU2R(WJ<0P#L"O^H`BT<4>JUY>.JYF\18XI/<2PQ@>"SL MVL/15'=`G-T+)4-4H?4?^FQ*$-3CL*3^W&,?ELD^!V>0E9]%[,6J@P,I'IV6 M<+`24?'8HK,HU7=5D)`(%S)-WKY3^>,V%UVU.V*@DZ2AF_7I"G("@!XAN.U:>>M1[)`JY'V[NE>3UFEA0KS;BRBWC-2E>)85( MY\>5"16FVM,J$>,-E;_Z!8%O(V!_&1>,X`\:E/V&>-&;R>?R M+Q"/)(R:QD6Y3@DW3$$TRE(4I0?WTGKX3V\N&1%E>YF!*(JY=IS_>(.2GEJ](P@"*DK.].R+>MU6X:_62!Q6-0JLZR!:?0X95H^S;T)\-5W/ M8;'8?V/P7=\3&(>W6PLC%.A*R,68(8V8$%DXU/`U7Z?"E=3:POA7%^X/R=^2 MJL9PQY!7J$4Q_M)EUZU9&RSB/92\EBMRW=+$;@JF`.VR;Y4J*@ZJ('T.F8IP M`P47-9G*=>]K.M7.#N9(9A>9%1(AXL569:"OP-*D#8U(-1MJ\],[!?[B>@8\WIT MG;W0[\I990D^7"";VKYH'RT6WKUF?LA'NB`,W)D!'M@!0NF:L+& MU]W,/E;:*']TN<#+>31>FO`72X^YE5BE*5,B*VXKR6OCOJG8"\R%W[-9S"74 MT_[5:YZ"RAEYMS_%?(6L;J'KX"-V'C2C$?;MKJ#NU1B;W5YNI37>*PFV!VIU MVJG9>Q[DBA',?+1RX`)FTI#R*"3IJJ'-)PB0X5+6[>RN4N8Z7UG%D+5[*;_`$Y%I\P1NK#X%&`93\=589"SC)5J_9%@P;Q+ M'/K4W7I"/?1ZZAP2:K2"'DG]&@)JZL&#C[B%--W4'&LIV.2TR4]J%5> MV/9QVS$<5-?5<>OR-.*LA!1CLI:IJJ'6SPU8QU'5J$K9*O=+)@]CBBZT:ZYJ MA*HJ]K:E_MEDIEC+=8-D?_JB;K,#(54YD9IG'NXMB5NU3[YD"*'39RWF2EO/ MS1-%'G#=))';EZ'TE1D]-B"%5W#`%"RL_)F`!.GEO8XF"S%J8IINN_AO%+=! M"4]9I`YE4$_GWC3@<(ME1/)(U'%%_@H%?,GQUL^(Q_P"V MV*VS'G.27D?SDE<\I'/ZGP\*"@\M+RGC*F9FQW;\69#C%IFDWJ$=U^RQC>3D MX9=Y%O`#O(I2<,[823,^I0$#)*D'EH.I1$!ZQ>1N\-D8(;`5:QH[P9 M#YFW:,MOLB^=.Y3!+;-ZC7'DDC(/?4).(=?)UMM:_0)1V83NF9)0B+@YC&.` MF$1'2;GWC[#=9)<[/9XE^QH`%NS;`S*1]K;N8PX\%;T]AL*#64VWL=UJTQCX M&WOLTO6G8EK,75("":LI"H'XD[L.?U'_/S,HCHB\<.%%3.4@'KU.8YS0%E[B=CM(\B MLIAGERPI=/-&)&D'D.1(H%K50``NU/`:LE][9=9O)<8\1NK6+$;6L<$GIQQG M:K<>)JS4^IB:MO4FIUN>==E^--PN4\0Y@NULRS$V[!,@K,XR)3+P:NPM?FW9 M@))S7I98MTF\DIAD0K5T94QB*-2@F!0YB+'!]RRG7L5>X:SCM#99!>,W./FS M(-U7D3L%.XIX'?QT^[!T7%=ERUEF[V:]2]QYK#Z\^V[%-'R4;+M;P1;87LD_(V:.?EKJ<"TE!B(::D MU5FD7\^$8D?010,(FZIV;W4[!(9KB.#'PY:>V,#W<@]H.MQ>A!+7EQ^"-]EE:\M6?6IZDMV2#A_(-V#@ZJ`* M/3H-W@@X33*J1,Q&G^Y78UPUABE6V63&$?CW"Q#\F(!@W%9*[+4"M%!(V8D$ MU>GVLZRV;R&8E>[>'*5-S;-,?Q96(92S1@#D0&/&K$*:,`"!368+Q@X&8_AK M#6V]9]RYC+#4U'6'%F$\L937MF**A+0A3EK:X001#"4LJ-53-T1J,R^D46B8 M=!2"7EP[G]T\_(+J6R@L+/)WJ%+BZ@@$<\BMNXY7.2O<78N'M[6XN#);1L!13PXAG"`T02,P4;4IIX*%LPQICS(6E6Q,K2SIT&SKU.6G(8R2R M#VNR$HV;N%E8&527$KMN`%!L9:+-XY8&O(35/4C$BJWDP M4[57^4^(\1OJ4[1URP[9AI<'E&G3'SBDGI/Z;$5KQ)`/TD_AN@)R]1$$B% M$1TU%EE9T\PF)BP6+AQ-O+/+;0+Q M5IG]23B/M!;:H`V'P%`-18B/'KAN%W3OMX[6[YT4S9)F4;23]WE)\O7G]7.H MDHG07=>&/!HI16@-T01C^H"I@B00-U!U#;)O<3-3=37I4D5B,$AY!1`H<2;_ M`-3GX^IN?J^9U3H/;+`6_<&[RMQD#GWV9C.2A3;^GQXU]*BCZ*TVTT^U"NQ> M<]Y.Z+>PKCIY3F,8QAMI^))B?KDE7+%?*WCUXI-Y`R6X9S+5F_/&V*RO&L;$ M.`3)W(R)#F/5H69[;=38+I>)Z0MR)F8F_N%5PZ1/,*10@K4?3'5W%3220U&H M+I5I%V+OF8[^]L8(T5,?;,R%'E2+ZIIR&H?KDXQH:#Z(Z5.G8LWCZQ,_RS?, MR8\R'GC`%LRP9LMEIM@G)(TJN9(?M$U$DYRPP;J&FVK2RF15,4TE&_(OC=9C M=WN&,<8>V]Q,M'B(,)DK>QR%I:"ENUU#ZCP`FO%'#+5*[^F_)/+C3;4Y>>VF M&GS,^;QEUDL=>W9!N!:3^DDQ`IR=2K`-3Q9.+5)-:U.O&/\`'9@6%R[B#--; MF.5W4@Y744 M,H!A`027W#[!-B;S"7*VLEKD)EDF)A4,744C*D4"^DH"QJH"J!0#2Q^V77(, MQ8YRV>]BO,?'P@03$HJDDNI#!BPF8EI2S%G)))U\7(_C8PUDZ/=M'+XHF*JJ8G2 M4CG$^Y6:Q-M9QP6N.DN\*(U_>/?MDY)&:_:;U" MYW)D+&-5QZP>D(QL!'Q*<1X[<=O\]5D0_AZP!!XS0PE M&YNWA-,'J(D;SN&T-P,HACVSHBN#EZUE(E&&([91DLL`BZ91[ADT5_X8#J(Z MG-[S]BFR!SQG68L2,#%DV;>(!6GX@O>![*6BVR MITITV,T>TP73B/FHZ:K3Y-0YE6S]JYZEE5%.H#J*&-7,;[B]BL_S8[PPW]GD MI?4N(KE/51Y!X/2JE77R*L```/`#5DR?MCUB^2P:Q_)QUWBX_2MI;23TI4B\ M#'4AE934UY*34L:[FM96S[%N-LH;NO*?@_(T=D2[8KS7!8>J,3.Y$AK\W?90 M@:'37]6N\R%^EH*)2DY^'GW*)CNB+$5.X$JK<#)EZ@U3NN7RF+Z9U+.XY[:# M*6)GD80F.D+32!XD,08T5H]@M.-"0=S360=$PV*R_?>X]83 MH-!,($3`!$.'V2]V.QY`W<]O!C[3(W\9CN;BWAX32HWW`N68KSI] M90*6\SIEC/9OK&/_``X;JXR5]C)6,(@/&IXARP'D*:S+ M)XQ,,R68\J9SI^6]S^)+UFY$[/*J^,\SO8QE;X\X``1RY)^'LC^+:MBZD:@Q M<-A8IB)&PHEY2\60$D[MR!YG=JT& MOK>>T.!FSMWV&QO*S`_RMS1V``^T*PXC[::?)#9'MH;;6WF MSAOC5@A@%_#$BGM21?22;QXX),-K(2R.K"1T$VXMQ;0R1DPDC+"Y!\D177X0 M`(-N[]F;M`[D]TQSZRW1$M0.N/' MQ:,$AB>0?F7^XR@?.>L?(>K?R/S77T?Q>CC0^I?W MU^W3?V_S_:/KY\^/I5^CU./J;E-9=W;_;G]QA_N;C^\?1Q]/GZM/J M]/GZ6_&O/ASV^[RUL:7X.=*/R_\`65T=M+Y?L?U?=KL]LO9[':^#L]G3HZ?A MZ/9RX9O^?OS_`&7YU_%^/G\Z_P`:ZD4_;*#T_P!]XUVI^53P\J>5/AM3PUHF M`/Z!/QQD_P`+NG\>/GGVGUU^)7U'ZSZ!(^O_`$M^(W_+_7?IOO>K>E_S7RW3 M\URZ.)/L/]^_L2_N7_T'$?Z7I\*IZ>].=.'/S^W41UG_`&W_`+CD_:Z_ MW)4_ZWJ7CJQ[ER^[C-/I_Q_QUK'E\M'QUHT7+[/MX3:OS MTAI3Y:'+A33STNARU]VO!_GI-J_.FB'I]^G!Y_/1M\M#X=/=I^W@\_GHV^5- M*X0T\]*/EHOAY>S[.#;^.D^G;0YGWZ>_\`?PHI7YZ0 M4IMX:`=/NTX-J?+2[:/EQRO'^71H^7'0IY:-)^'G[/;SX/\`.FCS^>@/3[_S MA[==-?=]G"&E-_#1\-'RY?=P;4/P\]!\=_'0Y>[@%/+1H!I[N%V\M(*>6B^' 5[/;]_P#?P&GGXZ!32N$V_AI=?__9 ` end